

## **Decree**

**No .../2026 of [date] of the Minister for the Interior**

### **amending Decree No 78/2022 of 28 December of the Ministry of the Interior on controlled substances**

[1] The Government places great emphasis on taking effective action against the spread of designer drugs in order to minimise the health-related and social problems arising from their consumption.

[2] By adding the new substances to the list, they are subject to the same legal assessment as narcotic drugs: their production, distribution, possession or consumption may have criminal consequences.

[3] Thanks to the measure and due to strict control, risks to public health, including the exposure of the target consumer group, can be reduced.

[4] Based on the authorisation granted under Section 32(5a) of Act XCV of 2005 on medicinal products for human use and on the amendment of other regulations related to medicinal products, and acting within my duties as defined in Section 66(1)(26) of Government Decree No 182/2022 of 24 May on the scope of duties and powers of members of the Government, I hereby order the following:

#### **Section 1**

In Decree No 78/2022 of 28 December of the Ministry of the Interior on controlled substances (hereinafter: 'Decree'), the following point (h) is added to Section 3(1):

*(This Decree serves to ensure compliance with)*

'(h) Commission Delegated Directive (EU) 2025/2062 of 14 October 2025 amending the Annex to Council Framework Decision 2004/757/JHA as regards the inclusion of new psychoactive substances in the definition of drug'.

#### **Section 2**

(1) Annex 2 to the Decree is amended in accordance with *Annex 1* hereto.

(2) Annex 3 to the Decree is amended in accordance with *Annex 2* hereto.

#### **Section 3**

In Section 3(1)(g) of the Decree, the words "the Directive" shall be replaced by "the Directive,".

#### **Section 4**

This Decree shall enter into force on the tenth day following its publication.

## **Section 5**

The requirement for the prior notification of this draft decree, as stipulated in Articles 5 to 7 of Directive (EU) 2015/1535 of the European Parliament and of the Council of 9 September 2015 laying down a procedure for the provision of information in the field of technical regulations and of rules on Information Society services, has been met.

## **Section 6**

Section 2(1) and Annex 1 of this Decree serve to ensure compliance with Commission Delegated Directive (EU) 2025/2062 of 14 October 2025 amending the Annex to Council Framework Decision 2004/757/JHA as regards the inclusion of new psychoactive substances in the definition of drug.

Dr. Pintér Sándor  
Minister for the Interior

Annex 1 to Decree No .../2026 of the Ministry of the Interior

The following rows 118–120 are added to the table in point 1.1 of Annex 2 of the Decree:

	<i>A</i>	<i>B</i>	<i>C</i>	<i>D</i>	<i>E</i>
1	<i>Official name (Hungarian name)</i>	<i>Other name or abbreviation, spelling commonly used abroad</i>	<i>Chemical name / Description</i>	<i>Molecular formula</i>	<i>InChIKey chemical identifier]</i>

“

118	2-MMC <sup>EU</sup>	2-Methylmethcathinone	2-(methylamino)-1-(2-methylphenyl)propan-1-one <sup>EU</sup>	C <sub>11</sub> H <sub>15</sub> NO	PRGXFAWAMOFULD-UHFFFAOYSA-N
119	4-BMC <sup>EU</sup>	4-bromomethcathinone, Brepheдрone	1-(4-bromophenyl)-2-(methylamino)propan-1-one <sup>EU</sup>	C <sub>10</sub> H <sub>12</sub> BrNO	OOJXMFNDUXHDOV-UHFFFAOYSA-N
120	NEP (N-etil-norpentedron) <sup>EU</sup>	N-ethylnorpentedrone	2-(ethylamino)-1-phenylpentan-1-one <sup>EU</sup>	C <sub>13</sub> H <sub>19</sub> NO	QQAHEGDXEXIQPR-UHFFFAOYSA-N

”

The following rows 395–408 are added to the table in point 6.1 of Annex 3 of the Decree:

	<i>[A</i>	<i>B</i>	<i>C</i>	<i>D</i>
1	<i>Official name (or other name or abbreviation, or another type of spelling commonly used abroad)</i>	<i>Chemical name</i>	<i>Molecular formula</i>	<i>InChIKey chemical identifier]</i>
395	2-allyl-delta-8-THC	6,6,9-trimethyl-3-pentyl-2-(prop-2-en-1-yl)-6a,7,10,10a-tetrahydro-6H-dibenzo[b,d]pyran-1-ol	C <sub>24</sub> H <sub>34</sub> O <sub>2</sub>	CFETYQLRAHKLPE-UHFFFAOYSA-N
396	2-allyl-8-THC-methylcarbonate	methyl 6,6,9-trimethyl-3-pentyl-2-(prop-2-en-1-yl)-6a,7,10,10a-tetrahydro-6H-dibenzo[b,d]pyran-1-yl carbonate	C <sub>26</sub> H <sub>36</sub> O <sub>4</sub>	BZZUNSSZOKHVAE-UHFFFAOYSA-N
397	delta-8-THC-methylcarbonate	methyl 6,6,9-trimethyl-3-pentyl-6a,7,10,10a-tetrahydro-6H-dibenzo[b,d]pyran-1-yl carbonate	C <sub>23</sub> H <sub>32</sub> O <sub>4</sub>	RFLYYJVULKALGW-UHFFFAOYSA-N
398	protodesnitazene	N,N-diethyl-2-{2-[(4-propoxyphenyl)methyl]-1H-1,3-benzimidazol-1-yl}ethan-1-amine	C <sub>23</sub> H <sub>31</sub> N <sub>3</sub> O	CEHFMRGBRNNSCM-UHFFFAOYSA-N
399	CUMYL-PMINACA	1-pentyl-N-(2-phenylpropan-2-yl)-4,5,6,7-tetrahydro-1H-4,7-methanoindazole-3-carboxamide	C <sub>23</sub> H <sub>31</sub> N <sub>3</sub> O	FOMJQFIIIIGVOAU-UHFFFAOYSA-N
400	MADMB-4en-PINACA	N-[3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-1-(pent-4-en-1-yl)-1H-indazole-3-carboxamide	C <sub>20</sub> H <sub>28</sub> N <sub>4</sub> O <sub>2</sub>	PCCKVWBDUXLKSR-UHFFFAOYSA-N
401	ADMB-FUBBIOCA	N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-3-[(4-fluorophenyl)methyl]-2-oxo-2,3-dihydro-1H-1,3-benzimidazole-1-carboxamide	C <sub>21</sub> H <sub>23</sub> FN <sub>4</sub> O <sub>3</sub>	GXSHFTRGNMMPGQ-UHFFFAOYSA-N
402	2-allyl-delta-8-THC-O-acetate	6,6,9-trimethyl-3-pentyl-2-(prop-2-en-1-yl)-6a,7,10,10a-tetrahydro-6H-dibenzo[b,d]pyran-1-yl acetate	C <sub>26</sub> H <sub>36</sub> O <sub>3</sub>	MMVPONAFVYVEOO-UHFFFAOYSA-N
403	delta-9-THCP-methylcarbonate	methyl 6,6,9-trimethyl-3-heptyl-6a,7,8,10a-tetrahydro-6H-dibenzo[b,d]pyran-1-yl carbonate	C <sub>25</sub> H <sub>36</sub> O <sub>4</sub>	COPHQVCDZOVZHM-UHFFFAOYSA-N

404	2-formyl-delta-9-THCP	6,6,9-trimethyl-3-heptyl-2-formyl-6a,7,8,10a-tetrahydro-6H-dibenzo[b,d]pyran-1-ol	C <sub>24</sub> H <sub>34</sub> O <sub>3</sub>	OIDRCZJHZWMHEC-UHFFFAOYSA-N
405	HHC-TBDMS	tert-butyl[(3-pentyl-6,6,9-trimethyl-6a,7,8,9,10,10a-hexahydro-6H-dibenzo[b,d]pyran-1-yl)oxy]di(methyl)silane	C <sub>27</sub> H <sub>46</sub> O <sub>2</sub> Si	GQATYCQLGPFHCK-UHFFFAOYSA-N
406	N-propyl ephenidine	N-(1,2-diphenylethyl)propan-1-amine	C <sub>17</sub> H <sub>21</sub> N	QDJKYFSVYJISOP-UHFFFAOYSA-N
407	tilmetamine	2-(methylamino)-2-(thiophen-2-yl)cyclohexan-1-one	C <sub>11</sub> H <sub>15</sub> NOS	UIKFZAUDYKWKI-UHFFFAOYSA-N
408	avizafone	2,6-diamino-N-{2-[(2-benzoyl-4-chlorophenyl)(methyl)amino]-2-oxoethyl}hexanamide	C <sub>22</sub> H <sub>27</sub> ClN <sub>4</sub> O <sub>3</sub>	LTKOVYBBGBGKTA-UHFFFAOYSA-N

”